Asia Pacific Animal Model Market size was over USD 3.9 billion in 2020 and is projected to expand at 7.5% CAGR from 2021 to 2027.
Get more details on this report - Request Free Sample PDF
The rising number of animal model applications in the healthcare domain in the Asia Pacific region will boost the market demand. Animal models have been a significant research tool for many years and are becoming even more essential in the advent of the molecular-genomic revolution. For instance, China has access to huge colonies of monkeys and other species thus, scientist in China face less public inspection than counterparts in Europe and the U.S. China have become the center of the CRISPR animal kingdom, appealing top researchers attributed to the Chinese government’s massive investment in new services and determined research projects.
In 2020, monkeys segment accounted for Asia Pacific animal model market revenue of more than 143 million attributed to the similarity to humans in physiology, neuroanatomy, reproduction, development, etc. The research performs using the monkey model enables scientists to make numerous investigations regarding AIDS to make it a manageable disease and to inhibit infection, improved treatments, and potential cures. Researchers developed genetically modified monkeys with a revolutionary novel process that allows researchers to cut and paste DNA in living organisms. The scientist of China created monkeys using the CRISPR procedure owing to its enormous potential in different diseases including Alzheimer's and Parkinson's.
In Asia Pacific animal model market, CRISPR segment held significant size of over USD 1,229 million in 2020 due to its simplicity, efficiency, and enable robust procedures. The key significance of CRISPR-Cas9 in embryonic stem cells is that Cas9-induced DNA damage raises the occurrence of homologous recombination events by multiple order of magnitudes. In 2020, the scientists of Australia in collaboration with China researchers successfully applied CRISPR/Cas9 technology to promote the advancement of pig research. Currently, the application of the CRISPR/Ca9 method on animals in immunity, obesity, aging, etc. is progressively expanding and showing benefits over the conventional techniques.
The research & development application segment will register growth of 7.2% during the forecast timeframe. The high segment growth in the Asia Pacific animal model market is owing to the similarity of animal models to humans in terms of genetics, ease of manipulation, and importance of animal models in each area of medical research. In Japan, the Central Institute for Experimental Animals developed the transgenic rasH2 model that is used for preclinical carcinogenicity testing. Animal models of renal ailment have delivered valuable insights into the pathogenesis of kidney disorders. Rabbits are the most used animal model for research of hyperlipidaemia and atherosclerosis. They are sensitive to a high-fat diet and their absorption rate of exogenous cholesterol is over 95%. Thus, the development of novel animal models is an important task for further examination of the pathological process of ailments such as infectious, genetic, cardiovascular, etc.
The human segment value was around USD 3,115 million in 2020. In April 2020, the government of China announced the approval to build a national animal model resource bank for human diseases. These animal models of human disorders are significantly used for drug screening and vaccine research. As per the recently published article, the area of genetically altered animal models is accelerating, particularly in Japan and China that may lead to improve understanding of neurological diseases and validation of potential therapeutic interventions. Across a variety of human ailments comprising hypertension, animal models have been useful for delivering incisive experimental strategies not possible in human studies. New tools to categorize compounds appropriate for parasitological cure in humans have developed using animal disease models that are an integral part of the drug discovery process.
The companies segment size in the Asia Pacific animal model market exceeded USD 2,378 million in 2020 led by the advancement of knowledge pertaining to animals, humans, and effective treatment of disease symptoms or in many cases disease cures. The pharmaceutical and biotechnology companies are required to follow the animal rule to provide substantial evidence of the effectiveness of a drug. Advances in genomic research have provided numerous benefits for the pharmaceutical industry owing to the use of animals in the vaccine discovery process that leading to the replacement with genetically modified animals. Animals involved in pharmaceutical and biological research are as diverse as the types of research and must be considered on a case-by-case basis. Additionally, novel technologies enable more information to be obtained from each animal and integrate it to obtain better outcomes.
China animal model market revenue in 2020 was over USD 1,222 million. This high size is due to the country's rapid development of life science and biotechnologies such as gene editing and deep sequencing. Scientists in the country are using AI to further simulate the effect of a drug on the targeted animal models that will greatly shorten the time and expenses of the drug discovery procedures. The researchers are focused on screening the drugs using personalized animal models integrating with traditional disease models to increase the success rate of a process.
Some of the key industry players are Charles River, Envigo, genOway, Cyagen, HarbourMed, PharmaLegacy, Transgenic Inc., and Taconic Biosciences, among others.
The Asia Pacific animal model market players are undertaking several inorganic strategies such as collaborations, mergers, and acquisitions to maintain their position. For instance, in March 2019, the Charles River announced an agreement with Crown Bioscience Inc. to expand its access to Zucker Diabetic Sprague-Dawley rat model. This strategic collaboration allowed better global model availability for drug discovery in diabetes, metabolic diseases, obesity, etc. Hence, this strategic move further assisted the company in enhancing their product portfolio and industrial position.